 |
| Jack Howarth |
Jack Howarth, a veteran financial and pharmaceutical PR executive, has joined MiMedx Group as senior VP-investor relations.
The Marietta, Ga.-based advanced wound care and therapeutic biologics company celebrated its relisting on the Nasdaq last month. after being delisted two years ago because its accounting practice fell short of Securities and Exchange Commission standards.
CEO Timothy Wright called rejoining the Nasdaq “a momentous occasion that represents a transformative milestone for MiMedx’s employees and shareholders.”
The stock of the company, which posted a $32M loss on nine-month revenues of $180M, trades at $6 per share. 52-week range is $7.95 and $2.95.
Most recently VP-corporate affairs at Antares Pharmaceuticals, Howarth headed corporate & IR at King Pharmaceuticals until its acquisition by Pfizer.
He held top jobs at Alpharma, KOS Pharmaceuticals, Elan Corp. and worked in finance and corporate development at Warner-Lambert prior to Pfizer acquiring it in 2000.
Wright said the addition of Howarth demonstrates MiMedx’s “commitment to communications as a core corporate responsibility."
The Blueshirt Group handles Lime as the San Francisco-based electric bike/scooter company has filed paperwork for an initial public offering, which will have an expected valuation in the $2B range.
Why CEOs need their CFOs and CCOs on the same page.
ICR handles Rare Earths Americas as the Manchester, Georgia-based company plans an initial public offering valued in the $370M range.
DGA Group handles takeover target Intertek as the London-based quality assurance testing company as it launches a strategic review of its operations.
